Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Willer, B.
Right arrow Articles by Krähenbühl, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Willer, B.
Right arrow Articles by Krähenbühl, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2000; 39: 293-298
© 2000 British Society for Rheumatology

Effects of creatine supplementation on muscle weakness in patients with rheumatoid arthritis

B. Willer, G. Stucki1,, H. Hoppeler2, P. Brühlmann and S. Krähenbühl3

Department of Rheumatology and Physical Medicine, University Hospital of Zurich, Switzerland,
1 Department of Physical Medicine and Rehabilitation and Institute of Medical Balneology and Climatology, Ludwig-Maximilians-University, Munich, Germany and
2 Institute of Anatomy, University of Bern and
3 Institute of Clinical Pharmacology, University of Bern, Switzerland

Background and objectives. Patients with rheumatoid arthritis (RA) frequently suffer from muscle weakness. Oral administration of creatine has been shown to improve muscle strength in healthy subjects. The objective of this study was to examine the effect of oral creatine supplementation on muscle weakness, disease activity and activities of daily living in patients with RA.

Methods. During a period of 3 weeks, 12 patients with RA were treated with creatine monohydrate (20 g/day for 5 days followed by 2 g/day for 16 days). They were examined on entry and at the end of the study. The patients were investigated clinically, blood and urine samples were obtained, muscle biopsies were performed before and after treatment, muscle strength was determined, and self-administered patient questionnaires were completed.

Results. From all patients we were able to obtain full clinical and questionnaire data, while biopsies were taken from 12 patients at the start and from nine patients at the end of the study. Muscle strength, as determined by the muscle strength index, increased in eight of 12 patients. In contrast, physical functional ability and disease activity did not change significantly. The creatine concentration in serum and skeletal muscle increased significantly, while creatine phosphate and total creatine did not increase in skeletal muscle. The skeletal muscle creatine content was associated with muscle strength at baseline but not after administration of creatine. The changes in muscle strength were not associated with the changes in skeletal muscle creatine or creatine phosphate.

Conclusion. Although the skeletal muscle creatine content and muscle strength increased with creatine administration in some patients with RA, a clear clinical benefit could not be demonstrated for this treatment when the patients were considered as one group.

KEY WORDS: Creatine kinase, Creatine supplementation, Muscle strength, Rheumatoid arthritis.

Correspondence to: G. Stucki.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
A. M. Persky and G. A. Brazeau
Clinical Pharmacology of the Dietary Supplement Creatine Monohydrate
Pharmacol. Rev., May 11, 2001; (2001) 1.
[Abstract] [Full Text]


Home page
Pharmacol. Rev.Home page
A. M. Persky and G. A. Brazeau
Clinical Pharmacology of the Dietary Supplement Creatine Monohydrate
Pharmacol. Rev., June 1, 2001; 53(2): 161 - 176.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.